GlassScriptPhysician profile
Waleed S Lashin
NPI 1477590644
$8,294.70
in general payments reported to CMS, 2019-2025
51 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $969 · 2021: $835 · 2022: $1,242 · 2023: $1,011 · 2024: $1,564 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,243.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.04 | 2020-2025 | |
| Novo Nordisk INC | $1,026.94 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $685.76 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $554.90 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $453.02 | 2020-2025 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $392.51 | 2019-2023 | Linzess |
| Lilly USA, LLC | $358.63 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $234.14 | 2019-2025 | |
| Abbott Laboratories | $228.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $214.57 | 2020-2023 | Verquvo, Belsomra |
| Baxter Healthcare | $202.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $193.65 | 2022-2023 | |
| Amarin Pharma, INC. | $184.61 | 2019-2023 | |
| Allergan, INC. | $175.32 | 2019-2020 | |
| Valeritas, INC. | $160.94 | 2019 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waleed Lashin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.